



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 16-Nov-2022

Revision Number 3

**72752 - Gatifloxacin**

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

**Document Number** DX21147

**Product Name** Gatifloxacin

**Synonyms** AM 1155; BMS 206584-01; PD 135432;  
1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;

**Pure substance/mixture** Substance

Contains 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid

**Molecular weight** 375.4

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Recommended Use** Laboratory chemicals

**Uses advised against** No information available

### 1.3. Details of the supplier of the safety data sheet

#### Manufacturer

STEMCELL Technologies SARL

40 Rue des Berges, Miniparc Polytec, Bâtiment Sirocco, 38000 Grenoble, France

+33 (0) 4 76 04 75 30

STEMCELL Technologies Germany GmbH

Stolberger Str. 200, 50933, Köln, Germany

+33 (0) 4 76 04 75 30

STEMCELL Technologies UK Ltd.

Building 7100, Cambridge Research Park, Beach Drive, Waterbeach, Cambridge, UK, CB25 9TL

+33 (0) 4 76 04 75 30

For further information, please contact

### 1.4. Emergency telephone number

**Emergency Telephone** No information available

**Emergency Telephone - \$45 - (EC)1272/2008**

**Europe** 112

## Section 2: HAZARDS IDENTIFICATION



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 16-Nov-2022

Revision Number 3

## 72752 - Gatifloxacin

### 2.1. Classification of the substance or mixture

Regulation (EC) No 1272/2008

Acute toxicity - Oral	Category 4 - (H302)
Acute toxicity - Dermal	Category 4 - (H312)
Acute toxicity - Inhalation (Dusts/Mists)	Category 4 - (H332)
Respiratory sensitization	Category 1 - (H334)
Skin sensitization	Category 1 - (H317)

### 2.2. Label elements

Contains 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid



#### Signal word

Danger

#### Hazard statements

##### Hazard statements

- H302 - Harmful if swallowed
- H312 - Harmful in contact with skin
- H317 - May cause an allergic skin reaction
- H332 - Harmful if inhaled
- H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled
- H303 - May be harmful if swallowed
- H313 - May be harmful in contact with skin
- H333 - May be harmful if inhaled

#### Precautionary Statements - EU (§28, 1272/2008)

- P280 - Wear protective gloves/protective clothing/eye protection/face protection
- P321 - Specific treatment (see supplemental instructions on the administration of antidotes on this label)
- P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
- P284 - In case of inadequate ventilation wear respiratory protection
- P304 + P340 - IF INHALED: Remove person to fresh air and keep comfortable for breathing
- P342 + P311 - If experiencing respiratory symptoms: Call a POISON CENTER or doctor
- P280 - Wear eye protection/ face protection

#### Additional information

This product requires tactile warnings if supplied to the general public

### 2.3. Other hazards

No information available



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 16-Nov-2022

Revision Number 3

**72752 - Gatifloxacin**

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

### 3.1 Substances

Chemical name	EC No.	CAS No.	Weight-%	Classification according to Regulation (EC) No. 1272/2008 [CLP]	REACH Registration Number
1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid	-	112811-59-3	100	Resp. Sens. 1 (H334) Acute Tox. 4 (H302) Acute Tox. 4 (H312) Acute Tox. 4 (H332) Skin Sens. 1 (H317)	No data available

Full text of H- and EUH-phrases: see section 16

## Section 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

<b>General advice</b>	Show this safety data sheet to the doctor in attendance.
<b>Inhalation</b>	May cause allergic respiratory reaction. Avoid direct contact with skin. Use barrier to give mouth-to-mouth resuscitation. Get immediate medical advice/attention. If breathing has stopped, give artificial respiration. Get medical attention immediately. Remove to fresh air.
<b>Eye contact</b>	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
<b>Skin contact</b>	Wash with soap and water. May cause an allergic skin reaction. Wash off immediately with plenty of water for at least 15 minutes. If symptoms persist, call a physician.
<b>Ingestion</b>	May produce an allergic reaction. Get immediate medical advice/attention. Do NOT induce vomiting. Clean mouth with water and drink afterwards plenty of water. Never give anything by mouth to an unconscious person.
<b>Self-protection of the first aider</b>	Avoid contact with skin, eyes or clothing. Avoid direct contact with skin. Use barrier to give mouth-to-mouth resuscitation. Ensure that medical personnel are aware of the material(s) involved, take precautions to protect themselves and prevent spread of contamination. Avoid breathing dust/fume/gas/mist/vapors/spray. Use personal protective equipment as required. See section 8 for more information.

### 4.2. Most important symptoms and effects, both acute and delayed

<b>Symptoms</b>	May cause allergy or asthma symptoms or breathing difficulties if inhaled. Itching. Rashes.
-----------------	---



## SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

**72752 - Gatifloxacin**

**Revision Date** 16-Nov-2022

**Revision Number** 3

Hives. Coughing and/ or wheezing. Difficulty in breathing.

### 4.3. Indication of any immediate medical attention and special treatment needed

**Note to physicians**

May cause sensitization in susceptible persons. Treat symptomatically.

## Section 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing media

**Suitable Extinguishing Media**

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

**Unsuitable Extinguishing Media**

No information available.

### 5.2. Special hazards arising from the substance or mixture

**Specific hazards arising from the chemical**

May cause sensitization by inhalation and skin contact. Product is or contains a sensitizer.  
May cause sensitization by skin contact.

### 5.3. Advice for firefighters

**Special protective equipment for fire-fighters**

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

## Section 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal precautions, protective equipment and emergency procedures

**Personal precautions**

Avoid contact with skin, eyes or clothing. Evacuate personnel to safe areas. Keep people away from and upwind of spill/leak. Ensure adequate ventilation. Avoid generation of dust. Do not breathe dust. Use personal protective equipment as required.

**Other Information**

Refer to protective measures listed in Sections 7 and 8.

**For emergency responders**

Use personal protection recommended in Section 8.

### 6.2. Environmental precautions

**Environmental precautions**

Prevent further leakage or spillage if safe to do so.

### 6.3. Methods and material for containment and cleaning up

**Methods for containment**

Prevent further leakage or spillage if safe to do so.

**Methods for cleaning up**

Take up mechanically, placing in appropriate containers for disposal.



## SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 16-Nov-2022

Revision Number 3

**72752 - Gatifloxacin**

**Prevention of secondary hazards** Clean contaminated objects and areas thoroughly observing environmental regulations.

### 6.4. Reference to other sections

**Reference to other sections** See section 8 for more information. See section 13 for more information.

## Section 7: HANDLING AND STORAGE

### 7.1. Precautions for safe handling

**Advice on safe handling** Provide extract ventilation to points where emissions occur. Remove contaminated clothing and shoes. Avoid contact with skin, eyes or clothing. In case of insufficient ventilation, wear suitable respiratory equipment. Take off contaminated clothing and wash before reuse. Handle in accordance with good industrial hygiene and safety practice. Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid generation of dust. Ensure adequate ventilation. Do not eat, drink or smoke when using this product.

**General hygiene considerations** Avoid contact with skin, eyes or clothing. Wear suitable gloves and eye/face protection. Remove and wash contaminated clothing and gloves, including the inside, before re-use. Avoid breathing dust/fume/gas/mist/vapors/spray. Do not eat, drink or smoke when using this product.

### 7.2. Conditions for safe storage, including any incompatibilities

**Storage Conditions** Store locked up. Store in accordance with information listed on the Product Information Sheet (PIS). Keep out of the reach of children.

### 7.3. Specific end use(s)

#### **Identified Uses**

**Risk Management Methods (RMM)** The information required is contained in this Material Safety Data Sheet.

## Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control parameters

**Exposure Limits** This product, as supplied, does not contain any hazardous materials with occupational exposure limits established by the region specific regulatory bodies.

**Derived No Effect Level (DNEL)** No information available.



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 16-Nov-2022

Revision Number 3

## 72752 - Gatifloxacin

**Predicted No Effect Concentration (PNEC)** No information available.

### 8.2. Exposure controls

#### Personal protective equipment

**Eye/face protection** Wear safety glasses with side shields (or goggles).

**Hand protection** Wear suitable gloves.

**Skin and body protection** Long sleeved clothing. Wear suitable protective clothing.

**Respiratory protection** No protective equipment is needed under normal use conditions. If exposure limits are exceeded or irritation is experienced, ventilation and evacuation may be required.

**General hygiene considerations** Avoid contact with skin, eyes or clothing. Wear suitable gloves and eye/face protection. Remove and wash contaminated clothing and gloves, including the inside, before re-use. Avoid breathing dust/fume/gas/mist/vapors/spray. Do not eat, drink or smoke when using this product.

**Environmental exposure controls** No information available.

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on basic physical and chemical properties

**Physical state** Solid  
**Appearance** Crystalline  
**Color** No information available  
**Odor** No data available.  
**Odor threshold** No data available

Property	Values	Remarks • Method
pH	No data available	None known
Melting point / freezing point	No data available	None known
Boiling point / boiling range	No data available	None known
Flash point	No data available	None known
Evaporation rate	No data available	None known
Flammability (solid, gas)	Product is not flammable.	
Flammability Limit in Air		None known
Upper flammability limit:	No data available	
Lower flammability limit:	No data available	
Vapor pressure	No data available	None known



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 16-Nov-2022

Revision Number 3

## 72752 - Gatifloxacin

Vapor density	No data available	None known
Relative density	No data available	None known
Water solubility	No data available	None known
Solubility(ies)	DMF: 10 mg/mL; DMF:PBS(pH 7.2)(1:1): 0.5 mg/mL; DMSO: 1 mg/mL with warming	
Partition coefficient	No data available	None known
Autoignition temperature	No data available	None known
Decomposition temperature	No data available	None known
Kinematic viscosity	No data available	None known
Dynamic viscosity	No data available	None known
Explosive properties	No information available	
Oxidizing properties	No information available	
<b>9.2. Other information</b>		
Softening point	No information available	
Molecular weight	375.4	
Molecular formula	C <sub>19</sub> H <sub>22</sub> FN <sub>3</sub> O <sub>4</sub>	
VOC Content (%)	No information available	
Liquid Density	No information available	
Bulk density	No information available	

## Section 10: STABILITY AND REACTIVITY

### 10.1. Reactivity

Reactivity No information available.

### 10.2. Chemical stability

Stability Stable under recommended transport or storage conditions.

### Explosion data

Sensitivity to Mechanical Impact None.

Sensitivity to Static Discharge None.

### 10.3. Possibility of hazardous reactions

Possibility of hazardous reactions None under normal processing.

Hazardous polymerization Hazardous polymerization does not occur.

### 10.4. Conditions to avoid

Conditions to avoid Excessive heat.



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 16-Nov-2022

Revision Number 3

## 72752 - Gatifloxacin

### 10.5. Incompatible materials

Incompatible materials Strong oxidizing agents.

### 10.6. Hazardous decomposition products

Hazardous decomposition products Carbon dioxide (CO<sub>2</sub>). Carbon monoxide. Hydrogen fluoride. Nitrogen oxides (NO<sub>x</sub>).

## Section 11: TOXICOLOGICAL INFORMATION

### 11.1. Information on toxicological effects

#### Information on likely routes of exposure

##### Product Information

Inhalation	May cause sensitization in susceptible persons. Specific test data for the substance or mixture is not available. Harmful by inhalation. (based on components).
Eye contact	Specific test data for the substance or mixture is not available.
Skin contact	May cause sensitization by skin contact. Specific test data for the substance or mixture is not available. Repeated or prolonged skin contact may cause allergic reactions with susceptible persons. May be harmful if absorbed through the skin. Harmful in contact with skin. (based on components).
Ingestion	May cause additional effects as listed under "Inhalation". Specific test data for the substance or mixture is not available. Harmful if swallowed. (based on components).

### Symptoms related to the physical, chemical and toxicological characteristics

Symptoms Symptoms of allergic reaction may include rash, itching, swelling, trouble breathing, tingling of the hands and feet, dizziness, lightheadedness, chest pain, muscle pain, or flushing. Itching. Rashes. Hives. Coughing and/ or wheezing.

### Numerical measures of toxicity

#### Acute toxicity

The following values are calculated based on chapter 3.1 of the GHS document

ATEmix (oral)	500.00 mg/kg
ATEmix (dermal)	1,100.00 mg/kg
ATEmix (inhalation-dust/mist)	1.50 mg/l

Unknown acute toxicity 100 % of the mixture consists of ingredient(s) of unknown toxicity.  
0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity.





# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 16-Nov-2022

Revision Number 3

## 72752 - Gatifloxacin

0 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity.  
 100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas).  
 100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor).  
 0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist).

### Product Information

### Delayed and immediate effects as well as chronic effects from short and long-term exposure

**Skin corrosion/irritation** No information available.

### Product Information

**Serious eye damage/eye irritation** No information available.

### Product Information

**Respiratory or skin sensitization** May cause sensitization by inhalation. May cause sensitization by skin contact.

### Product Information

**Germ cell mutagenicity** No information available.

### Product Information

**Carcinogenicity** No information available.

### Product Information

**Reproductive toxicity** No information available.

### Product Information

**STOT - single exposure** No information available.

### Product Information

**STOT - repeated exposure** No information available.

### Product Information

**Aspiration hazard** No information available.

## Section 12: ECOLOGICAL INFORMATION

### 12.1. Toxicity

**Ecotoxicity** The environmental impact of this product has not been fully investigated.

**Unknown aquatic toxicity** Contains 0 % of components with unknown hazards to the aquatic environment.

### Product Information



## SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 16-Nov-2022

Revision Number 3

### 72752 - Gatifloxacin

#### 12.2. Persistence and degradability

Persistence and degradability No information available.

#### 12.3. Bioaccumulative potential

Bioaccumulation No information available.

#### 12.4. Mobility in soil

Mobility in soil No information available.

#### 12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment No information available.

#### 12.6. Other adverse effects

Other adverse effects No information available.

### Section 13: DISPOSAL CONSIDERATIONS

#### 13.1. Waste treatment methods

Waste from residues/unused products Dispose of in accordance with local regulations. Dispose of waste in accordance with environmental legislation.

Contaminated packaging Do not reuse empty containers.

### Section 14: TRANSPORT INFORMATION

Note: Transport in accordance with local, state, and federal regulations.

#### IMDG

14.1 UN Number	Not regulated
14.2 UN proper shipping name	Not regulated
14.3 Transport hazard class(es)	Not regulated
14.4 Packing Group	Not regulated
14.5 Marine pollutant	Not applicable
14.6 Special Provisions	None
14.7. Transport in bulk according to	No information available



## SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 16-Nov-2022

Revision Number 3

### 72752 - Gatifloxacin

#### Annex II of MARPOL and the IBC Code

##### RID

14.1 UN Number	Not regulated
14.2 UN proper shipping name	Not regulated
14.3 Transport hazard class(es)	Not regulated
14.4 Packing Group	Not regulated
14.5 Environmental hazard	Not applicable
14.6 Special Provisions	None

##### ADR

14.1 UN Number	Not regulated
14.2 UN proper shipping name	Not regulated
14.3 Transport hazard class(es)	Not regulated
14.4 Packing Group	Not regulated
14.5 Environmental hazard	Not applicable
14.6 Special Provisions	None

##### IATA

	<b>Not regulated</b>
14.1 UN Number	Not regulated
14.2 UN proper shipping name	Not regulated
14.3 Transport hazard class(es)	Not regulated
14.4 Packing Group	Not regulated
14.5 Environmental hazard	Not applicable
14.6 Special Provisions	None

## Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

#### European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

#### Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

#### Persistent Organic Pollutants

Not applicable



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 16-Nov-2022

Revision Number 3

**72752 - Gatifloxacin**

Ozone-depleting substances (ODS) regulation (EC) 1005/2009 Not applicable

## International Inventories

TSCA	Does not comply
DSL/NDSL	Does not comply
EINECS/ELINCS	Does not comply
ENCS	Does not comply
IECSC	Does not comply
KECL	Does not comply
PICCS	Does not comply
AICS	Does not comply

## Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory  
**DSL/NDSL** - Canadian Domestic Substances List/Non-Domestic Substances List  
**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances  
**ENCS** - Japan Existing and New Chemical Substances  
**IECSC** - China Inventory of Existing Chemical Substances  
**KECL** - Korean Existing and Evaluated Chemical Substances  
**PICCS** - Philippines Inventory of Chemicals and Chemical Substances  
**AICS** - Australian Inventory of Chemical Substances

## 15.2. Chemical safety assessment

Chemical Safety Report No information available

## Section 16: OTHER INFORMATION

### Key or legend to abbreviations and acronyms used in the safety data sheet

#### Full text of H-Statements referred to under section 3

H302 - Harmful if swallowed  
H312 - Harmful in contact with skin  
H317 - May cause an allergic skin reaction  
H332 - Harmful if inhaled  
H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled

## Legend

SVHC: Substances of Very High Concern for Authorization:

## Legend Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

TWA	TWA (time-weighted average)	STEL	STEL (Short Term Exposure Limit)
Ceiling	Maximum limit value	*	Skin designation

Revision Date 16-Nov-2022



## SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

**72752 - Gatifloxacin**

**Revision Date** 16-Nov-2022

**Revision Number** 3

---

**This material safety data sheet complies with the requirements of Regulation (EC) No. 1907/2006**

### **Disclaimer**

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text. STEMCELL Technologies Inc. shall not be held liable for any damage resulting from handling or from contact with the product.